Journals / Turkish Journal of Urology / 2021 / Cilt: 47 - Sayı: 3

Correlation between the NGF levels and questionnaire forms in patients receiving antimuscarinic treatment and those receiving onabotulinum toxin-A injection

Pages
223–228
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Lack of correlation in patients receiving onaBoNT-A injection could be a result of differences in the mechanism of action.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To compare nerve growth factor (NGF) levels in patients who received antimuscarinic, versus onabotulinum toxin-A (onaBoNT-A) injection, as well as to investigate whether there is a correlation between NGF levels, and 8-item overactive bladder questionnaire(OAB-V8), urogenital distress inventory (UDI)-6, and incontinence impact questionnaire (IIQ)-7 forms.
📊
Key Findings & Data:An antimuscarinic was prescribed to 20 naive patients, and onaBoNT-A injection was administered to 20 patients, who were refractory to antimuscarinics.
💡
Conclusion & Impact:Lack of correlation in patients receiving onaBoNT-A injection could be a result of differences in the mechanism of action.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: To compare nerve growth factor (NGF) levels in patients who received antimuscarinic, versus onabotulinum toxin-A (onaBoNT-A) injection, as well as to investigate whether there is a correlation between NGF levels, and 8-item overactive bladder questionnaire(OAB-V8), urogenital distress inventory (UDI)-6, and incontinence impact questionnaire (IIQ)-7 forms. Material and methods: Fourty adult patients with OAB were enrolled in this prospective study. An antimuscarinic was prescribed to 20 naive patients, and onaBoNT-A injection was administered to 20 patients, who were refractory to antimuscarinics. Urine samples were obtained before, and after 3rd and 6th months of treatment, and NGF levels were measured. Symptom scores of OAB-V8, UDI-6,and IIQ-7 were recorded. Results: There was no significant difference between groups in terms of the initial OAB-V8, IIQ-7, and UDI6 scores, whereas NGF values showed no significant difference over time in onaBoNT-A group (p=0.069, p=0.069). NGF levels were significantly lower in 3rd and 6th months, in patients receiving antimuscarinic (p=0.003, p=0.007); a strong correlation was found in 3rd month between the NGF levels, OAB-V8 scores (r=0.704, p=0.001), and IIQ-7 scores (r=0.676, p=0.001), and a moderate correlation between NGF levels, and UDI-6 scores (r=0.583, p=0.007). In the 6th months, a very strong correlation was found between NGF levels, and OAB-V8 scores (r=0.811, p=0.004), and a strong correlation was found between NGF levels, and IIQ-7 scores (r=0.671, p=0.001). In onaBoNT-A group, there was no significant correlation between NGF levels, and other variables. Conclusion: NGF level might be a good marker to evaluate effectiveness of treatment in patients receiving antimuscarinics, owing to correlation of urinary NGF levels with symptom scores. Lack of correlation in patients receiving onaBoNT-A injection could be a result of differences in the mechanism of action.

🔖

Cite This Article

SAĞIR, S., BAYRAK, Ö., ŞEN, H., KUL, S., ERTURHAN, M. S., SEÇKİNER, İ. (2021). Correlation between the NGF levels and questionnaire forms in patients receiving antimuscarinic treatment and those receiving onabotulinum toxin-A injection. Turkish Journal of Urology, Cilt: 47 - Sayı: 3, 223–228. https://ajindex.com/articles/404252

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Antunes-Lopes T, Cruz F. Urinary biomarkers in overactive bladder: Revisiting the evidence. Eur Urol Focus 2019
  2. [Crossref] 2. Seth JH, Sahai A, Khan MS, van der Aa F, de Ridder D, Panicker JN, et al. Nerve growth factor (NGF): a potential urinary biomarker for overactivebladder syndrome (OAB)? BJU Int 2013
  3. [Crossref] 3. Cam C, Sakalli M, Ay P, Cam M, Karateke A. Validation of the short forms of the incontinence impact questionnaire (IIQ-7) and the urogenital distress inventory (UDI-6) in a Turkish population. Neurourol Urodyn 2007
  4. [Crossref] 4. Tarcan T, Mangir N, Ozgur MO, Akbal C. OAB-V8 Overactive Bladder Questionnaire Validation Study. Urology Bulletin 2012
  5. Steers WD, Tuttle JB. Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat Clin Pract Urol 2006
  6. [Crossref] 6. Kim JC, Park EY, Seo SI, Park YH, Hwang TK. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 2006
  7. [Crossref] 7. Antunes-Lopes T1, Carvalho-Barros S, Cruz CD, Cruz F, MartinsSilva C. Biomarkers in overactive bladder: a new objective and noninvasive tool? Adv Urol 2011
  8. 382431. [Crossref] 8. Qu HC, Yan S, Zhang XL, Zhu XW, Liu YL, Wang P. Urinary nerve growth factor levels could be a biomarker for overactive bladder symptom: a meta analysis. Genet Mol Res 2014
  9. [Crossref] 9. Kim SR, Moon YJ, Kim SK, Bai SW. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome. Yonsei Med J 2015
  10. [Crossref] 10. Liu HT, Lin H, Kuo HC. Increased serum nerve growth factor levels patients with overactive bladder syndrome refractory to antimuscarinic therapy. Neurourol Urodyn 2011
  11. [Crossref] 11. Antunes-Lopes T, Pinto R, Barros SC, Botelho F, Silva CM, Cruz CD, et al. Urinary neurotrophic factors in healthy individual sand patients with overactive bladder. J Urol 2013
  12. [Crossref] 12. Hegde SS. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 2006
  13. [Crossref] 13. Hsieh PF, Chiu HC, Chen KC, Chang CH, Chou EC. Botulinum toxin A for the treatment of overactive bladder. Toxins (Basel) 2016
  14. [Crossref] 14. Bhide AA, Cartwright R, Khullar V, Digesu GA. Biomarkers in overactive bladder. Int Urogynecol J 2013
  15. [Crossref] 15. Suh YS, Ko KJ, Kim TH, Lee HS, Sung HH, Cho WJ,